Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI
03 Maio 2023 - 10:08AM
Business Wire
Agenus (Nasdaq: AGEN), a leading immuno-oncology company
dedicated to developing innovative treatments for cancer and
infectious diseases, today announced a data update on botensilimab
(multifunctional CTLA-4 antibody) in combination with balstilimab
(PD-1 antibody) for patients with non-microsatellite
instability-high metastatic colorectal cancer (non-MSI-H mCRC) has
been selected for a late-breaking oral presentation at the upcoming
ESMO World Congress on Gastrointestinal Cancer (ESMO GI), to be
held June 28 – July 1, 2023 in Barcelona, Spain.
Presentation Details:
Abstract Title: Results from an expanded phase 1 trial of
botensilimab, a multifunctional anti-CTLA-4, plus balstilimab
(anti-PD-1) for metastatic heavily pretreated microsatellite stable
colorectal cancer (NCT03860272) Abstract Number: LBA-4
Presenting Author: Andrea J. Bullock, MD, MPH, Assistant
Professor of Medicine, Division of Medical Oncology, Beth Israel
Deaconess Medical Center Presentation Date and Time:
6/30/2023, 6:00pm – 6:10pm CEST
Data presented at the conference will be available to view in
the Publications section of the Agenus website
(https://agenusbio.com/publications) following the ESMO GI
Conference.
About Botensilimab
Botensilimab is a novel, multifunctional CTLA-4 investigational
antibody that has been designed to extend clinical benefits to
“cold” tumors that have not historically responded to standard of
care or investigational therapies. In addition to binding to the
CTLA-4 receptor, its Fc-enhanced structure induces a memory immune
response, downregulates regulatory T cells, and delivers better
priming and activation of T cells, thereby amplifying immune
responses.
In a Phase 1b clinical study of more than 350 patients,
botensilimab has demonstrated clinical responses in nine,
previously IO unresponsive, solid tumor cancers, either alone or in
combination with Agenus’ PD-1 antibody, balstilimab (data presented
at ASCO GI 2023, SGO 2023, CTOS 2022, SITC 2022). Agenus is
conducting global, randomized Phase 2 trials in non-MSI-H mCRC,
melanoma, and pancreatic cancer as part of its ACTIVATE trial
programs. Additional information about these botensilimab trials
can be found at www.clinicaltrials.gov under the identifiers
NCT05608044, NCT05630183, and NCT05529316, respectively. A global
Phase 3 trial in non-MSI-H mCRC is expected to launch in 2023.
About Agenus Agenus is a
clinical-stage immuno-oncology company focused on the discovery and
development of therapies that engage the body's immune system to
fight cancer and infections. The Company's vision is to expand the
patient populations benefiting from cancer immunotherapy by
pursuing combination approaches that leverage a broad repertoire of
antibody therapeutics, adoptive cell therapies (through its
subsidiary MiNK Therapeutics), and adjuvants (through its
subsidiary SaponiQx). The Company is equipped with a suite of
antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements relating to the use of
botensilimab and balstilimab, for instance, statements regarding
therapeutic benefit and efficacy, mechanism of action (including
validation of mechanism of action), potency, durability, and safety
profile (including the absence of specific toxicities) of the
Company’s therapeutic candidates; and any other statements
containing the words "may," "believes," "expects," "anticipates,"
"hopes," "intends," "plans," "forecasts," "estimates," "will,"
“establish,” “potential,” “superiority,” “best in class,” and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our most
recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K
filed with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230503005609/en/
Agenus Inc. Zack Armen Head of Investor Relations 917-362-1370
zack.armen@agenusbio.com
Agenus (NASDAQ:AGEN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Agenus (NASDAQ:AGEN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024